question: Although the original study was underpowered to properly address long-term outcomes, the results of this analysis suggest that TPVB, administered  whether as a single-injection or continuous infusion during the perioperative period, had little to no appreciable effect on local recurrence, metastasis or mortality after breast cancer surgery.